MCID: ANP009
MIFTS: 46

Anaplastic Oligodendroglioma

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Anaplastic Oligodendroglioma

MalaCards integrated aliases for Anaplastic Oligodendroglioma:

Name: Anaplastic Oligodendroglioma 49 55 51 69

Characteristics:

Orphanet epidemiological data:

55
anaplastic oligodendroglioma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Orphanet 55 ORPHA251630
UMLS via Orphanet 70 C0334590
ICD10 via Orphanet 33 C71.9
UMLS 69 C0334590

Summaries for Anaplastic Oligodendroglioma

NIH Rare Diseases : 49 This condition doesn't have a summary yet. Please see our page(s) on Oligodendroglioma.

MalaCards based summary : Anaplastic Oligodendroglioma is related to oligoastrocytoma and brain cancer, and has symptoms including seizures and headache. An important gene associated with Anaplastic Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial), and among its related pathways/superpathways are Relaxin signaling pathway and DNA Damage. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Anaplastic Oligodendroglioma

Diseases related to Anaplastic Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 30.9 IDH2 MGMT
2 brain cancer 29.3 EGFR IDH1 IDH2 MGMT
3 pilocytic astrocytoma 29.2 CDKN2A IDH1 MGMT
4 astrocytoma 29.2 CDKN2A EGFR IDH1 MGMT
5 oligodendroglioma 28.6 CDKN2A CDKN2C EGFR IDH1 IDH2 MGMT
6 glioblastoma 28.5 CDKN2A EGFR IDH1 IDH2 MGMT
7 glioma 28.3 CDKN2A EGFR IDH1 IDH2 POT1
8 interval angle-closure glaucoma 10.4 IDH1 IDH2
9 adult oligodendroglioma 10.3 IDH1 IDH2
10 enchondroma 10.3 IDH1 IDH2
11 intracranial chondrosarcoma 10.3 IDH1 IDH2
12 glioma susceptibility 1 10.3 IDH1 IDH2
13 cytogenetically normal acute myeloid leukemia 10.3 IDH1 IDH2
14 chondroblastic osteosarcoma 10.3 IDH1 IDH2
15 intraductal papilloma 10.3 IDH1 IDH2
16 multiple enchondromatosis, maffucci type 10.3 IDH1 IDH2
17 spindle cell hemangioma 10.3 IDH1 IDH2
18 adult astrocytic tumour 10.3 IDH1 IDH2
19 undifferentiated pleomorphic sarcoma 10.3 IDH1 IDH2
20 drug-induced mental disorder 10.3 IDH1 IDH2
21 drug psychosis 10.3 IDH1 IDH2
22 diffuse infiltrative lymphocytosis syndrome 10.3 IDH1 IDH2
23 2-hydroxyglutaric aciduria 10.3 IDH1 IDH2
24 breast papillary carcinoma 10.3 IDH1 IDH2
25 d-2-hydroxyglutaric aciduria 1 10.3 IDH1 IDH2
26 enchondromatosis, multiple, ollier type 10.3 IDH1 IDH2
27 bile duct adenocarcinoma 10.2 IDH1 IDH2
28 pleomorphic xanthoastrocytoma 10.2 IDH1 MGMT
29 gliomatosis cerebri 10.2 EGFR IDH1
30 spinal cord astrocytoma 10.2 IDH1 MGMT
31 blood group, i system 10.1
32 brain glioma 10.1 EGFR MGMT
33 leukemia 10.1
34 arteriovenous malformation 10.1
35 ependymoma 10.0 EGFR MGMT
36 fibrillary astrocytoma 10.0 IDH1 IDH2 MGMT
37 cerebritis 10.0
38 anaplastic oligoastrocytoma 10.0
39 intrahepatic cholangiocarcinoma 10.0 EGFR IDH1 IDH2
40 malignant peritoneal mesothelioma 9.9 CDKN2A EGFR
41 squamous cell carcinoma of the larynx 9.9 CDKN2A EGFR
42 gastric adenosquamous carcinoma 9.9 CDKN2A EGFR
43 anal squamous cell carcinoma 9.9 CDKN2A MGMT
44 primary central nervous system lymphoma 9.9 CDKN2A MGMT
45 cervical adenosquamous carcinoma 9.9 CDKN2A EGFR
46 breast giant fibroadenoma 9.9 CDKN2A MGMT
47 oropharynx cancer 9.9 CDKN2A EGFR
48 giant cell glioblastoma 9.9 EGFR IDH1 MGMT
49 peritoneal mesothelioma 9.9 CDKN2A EGFR
50 gliosarcoma 9.9 EGFR IDH1 MGMT

Graphical network of the top 20 diseases related to Anaplastic Oligodendroglioma:



Diseases related to Anaplastic Oligodendroglioma

Symptoms & Phenotypes for Anaplastic Oligodendroglioma

UMLS symptoms related to Anaplastic Oligodendroglioma:


seizures, headache

GenomeRNAi Phenotypes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.4 EGFR
2 Decreased viability GR00221-A-1 9.4 CDKN2A CDKN2C EGFR POT1
3 Decreased viability GR00221-A-3 9.4 CDKN2A POT1
4 Decreased viability GR00221-A-4 9.4 CDKN2A EGFR POT1
5 Decreased viability GR00301-A 9.4 CDKN2C
6 Decreased viability GR00342-S-2 9.4 CDKN2C

MGI Mouse Phenotypes related to Anaplastic Oligodendroglioma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.35 CDKN2A CDKN2C EGFR IDH2 MGMT
2 respiratory system MP:0005388 9.02 CDKN2A CDKN2C EGFR IDH1 MGMT

Drugs & Therapeutics for Anaplastic Oligodendroglioma

Drugs for Anaplastic Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 317)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
3
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2 154-93-8 2578
4
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
5
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
6
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
7
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
10
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
13
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5282379 5538
14
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538
15 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
16 Alkylating Agents Phase 3,Phase 2,Phase 1
17 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
18 Dermatologic Agents Phase 3,Phase 1,Phase 2
19 Keratolytic Agents Phase 3,Phase 1,Phase 2
20 Antimitotic Agents Phase 3,Phase 1,Phase 2
21 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
22 Analgesics Phase 3,Phase 1,Phase 2
23 Adjuvants, Anesthesia Phase 3
24 Central Nervous System Stimulants Phase 3,Phase 2
25 Cholinergic Agents Phase 3,Phase 2
26 Narcotics Phase 3
27 Cholinesterase Inhibitors Phase 3,Phase 2
28 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
29 Neurotransmitter Agents Phase 3,Phase 2
30 Analgesics, Opioid Phase 3
31 Nootropic Agents Phase 3,Phase 2
32 Anesthetics Phase 3,Phase 1
33 Anesthetics, General Phase 3
34 Anesthetics, Intravenous Phase 3
35 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
36 Liver Extracts Phase 3,Phase 2,Phase 1
37 Dopamine Agents Phase 3
38
Histamine Phosphate Phase 3 51-74-1 65513
39
Serotonin Phase 3 50-67-9 5202
40 Serotonin Agents Phase 3
41 Serotonin Antagonists Phase 3
42 Neurotransmitter Uptake Inhibitors Phase 3
43 Histamine Antagonists Phase 3
44 Histamine H1 Antagonists Phase 3
45 Dexmethylphenidate Hydrochloride Phase 3
46 Anti-Allergic Agents Phase 3
47 Dopamine Uptake Inhibitors Phase 3
48 Antipruritics Phase 3
49 Cola Nutraceutical Phase 3,Phase 1
50
Ethanol Approved Phase 1, Phase 2 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 234)

# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
3 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
6 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
7 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3 temozolomide
8 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
9 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
10 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
11 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
12 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
13 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
14 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
15 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
16 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Completed NCT00400816 Phase 2 temozolomide
17 Temozolomide in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00003465 Phase 2 temozolomide
18 Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
19 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
20 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
21 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
22 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
23 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
24 Bevacizumab for Recurrent Malignant Glioma Completed NCT00271609 Phase 2 Bevacizumab
25 Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas Completed NCT00047879 Phase 2 Thalidomide
26 BIBF 1120 for Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2 BIBF 1120
27 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2 ZD6474 (Vandetanib);Carboplatin
28 VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide Completed NCT00369590 Phase 2
29 FR901228 in Treating Patients With Recurrent High-Grade Gliomas Completed NCT00085540 Phase 1, Phase 2 depsipeptide
30 Fenretinide in Treating Patients With Recurrent Malignant Glioma Completed NCT00006080 Phase 2 fenretinide
31 Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00823797 Phase 2 Bendamustine Hydrochloride
32 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
33 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
34 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
35 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
36 Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas Completed NCT00042991 Phase 1, Phase 2 gefitinib
37 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
38 Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma Completed NCT00087061 Phase 1, Phase 2 gimatecan
39 Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma Completed NCT00404248 Phase 1, Phase 2 terameprocol
40 Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas Completed NCT00268359 Phase 2 irinotecan hydrochloride
41 Temozolomide in Treating Patients With Recurrent High-Grade Glioma Completed NCT00619112 Phase 2 temozolomide
42 Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma Completed NCT00005855 Phase 1, Phase 2 carmustine;efaproxiral
43 Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors Completed NCT00003574 Phase 2
44 Procarbazine in Treating Patients With Recurrent Brain Tumor Completed NCT00004004 Phase 1, Phase 2 procarbazine hydrochloride
45 Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00012038 Phase 1, Phase 2 irofulven
46 EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Completed NCT00006093 Phase 1, Phase 2 cilengitide
47 COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00004147 Phase 1, Phase 2 incyclinide
48 Study of Capecitabine to Treat Recurrent High Grade Gliomas Completed NCT00717197 Phase 2 Capecitabine
49 Antineoplaston Therapy in Treating Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
50 ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma Completed NCT00352313 Phase 1, Phase 2 ATN-161;carboplatin

Search NIH Clinical Center for Anaplastic Oligodendroglioma

Genetic Tests for Anaplastic Oligodendroglioma

Anatomical Context for Anaplastic Oligodendroglioma

MalaCards organs/tissues related to Anaplastic Oligodendroglioma:

38
Brain, Bone, Bone Marrow, T Cells, Liver, Spinal Cord, Endothelial

Publications for Anaplastic Oligodendroglioma

Articles related to Anaplastic Oligodendroglioma:

(show top 50) (show all 128)
# Title Authors Year
1
A Case of Anaplastic Oligodendroglioma With Extensive Extraneural Metastases Imaged With FDG PET. ( 29076897 )
2017
2
Genetic landscape of extreme responders with anaplastic oligodendroglioma. ( 28388591 )
2017
3
Multimodal (18)F-Fluciclovine PET/MRI and Ultrasound-Guided Neurosurgery of an Anaplastic Oligodendroglioma. ( 28844925 )
2017
4
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. ( 28696020 )
2017
5
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. ( 28472509 )
2017
6
Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients. ( 28024733 )
2016
7
The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients. ( 27651340 )
2016
8
Low-grade and anaplastic oligodendroglioma. ( 26948366 )
2016
9
Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. ( 26722084 )
2016
10
A rare presentation of anaplastic oligodendroglioma metastatic to bone marrow, mimicking blast cells. ( 27302043 )
2016
11
Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients. ( 27401158 )
2016
12
Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma. ( 26771849 )
2016
13
Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report. ( 26352098 )
2015
14
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. ( 25534576 )
2015
15
A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13-12. ( 26341368 )
2015
16
Somatostatin Receptors in an Anaplastic Oligodendroglioma Relapse Evidenced By 68Ga DOTANOC PET/CT. ( 26018682 )
2015
17
TCF12 is mutated in anaplastic oligodendroglioma. ( 26068201 )
2015
18
Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma. ( 26167373 )
2015
19
A case of mushroom-shaped anaplastic oligodendroglioma resembling meningioma and arteriovenous malformation: Inadequacies of diagnostic imaging. ( 26622514 )
2015
20
Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. ( 26354927 )
2015
21
Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). ( 24812135 )
2014
22
Increased 99mTc TRODAT-1 Uptake in Anaplastic Oligodendroglioma. ( 23603602 )
2014
23
Anaplastic oligodendroglioma arising from the brain stem and featuring 1p/19q co-deletion. ( 23711170 )
2014
24
Novel MSH6 mutations in treatment-naA^ve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. ( 25078279 )
2014
25
Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12. ( 25391968 )
2014
26
Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma. ( 25523732 )
2014
27
Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review. ( 24447608 )
2014
28
Cavernous angioma within the context of anaplastic oligodendroglioma: case report and review of the literature. ( 24844794 )
2014
29
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. ( 24162809 )
2014
30
Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma. ( 24527191 )
2013
31
A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. ( 23527265 )
2013
32
Differential diagnosis of small cell glioblastoma and anaplastic oligodendroglioma: a case report of an elderly man. ( 23979650 )
2013
33
Leukemia-like onset of bone marrow metastasis from anaplastic oligodendroglioma after 17A years of dormancy: an autopsy case report. ( 23900511 )
2013
34
Anaplastic oligodendroglioma in an adolescent with Lynch syndrome. ( 23255519 )
2013
35
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. ( 23071237 )
2013
36
Extraneural metastases of anaplastic oligodendroglioma. ( 24373094 )
2013
37
Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. ( 23681562 )
2013
38
Pitfalls of conservative treatments of multiple probable cerebral cavernous malformations (CCMs): clinicopathological features of CCMs coexisting with vasculogenic mimicry in an anaplastic oligodendroglioma. ( 24337536 )
2013
39
Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. ( 23907441 )
2013
40
Anaplastic oligodendroglioma: advances and treatment options. ( 23344797 )
2013
41
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. ( 23071247 )
2013
42
Feline anaplastic oligodendroglioma: long-term remission through radiation therapy and chemotherapy. ( 23651604 )
2013
43
1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. ( 23486687 )
2013
44
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. ( 23896377 )
2013
45
Minding the Ps and Qs: perseverance and quality studies lead to major advances in patients with anaplastic oligodendroglioma. ( 23071223 )
2013
46
Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management. ( 25054579 )
2013
47
Anaplastic oligodendroglioma involving the subcutaneous tissue of the scalp: report of an exceptional case and review of the literature. ( 22157246 )
2012
48
Anaplastic oligodendroglioma with ganglioglioma-like maturation. ( 22231405 )
2012
49
Long-term survival in a dog with anaplastic oligodendroglioma treated with radiation therapy and CCNU. ( 22785244 )
2012
50
Brain cancer. Fine-tuning chemoradiotherapy for anaplastic oligodendroglioma. ( 23149899 )
2012

Variations for Anaplastic Oligodendroglioma

Expression for Anaplastic Oligodendroglioma

Search GEO for disease gene expression data for Anaplastic Oligodendroglioma.

Pathways for Anaplastic Oligodendroglioma

Pathways related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.02 CDKN2A CDKN2C EGFR
2 11.9 CDKN2A CDKN2C MGMT
3 11.32 CDKN2A EGFR
4 11.25 EGFR POT1
5 11.22 EGFR IDH1
6 11.08 CDKN2A EGFR
7 10.84 CDKN2A EGFR MGMT
8 10.66 CDKN2A CDKN2C
9
Show member pathways
10.07 IDH1 IDH2

GO Terms for Anaplastic Oligodendroglioma

Biological processes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tricarboxylic acid cycle GO:0006099 9.43 IDH1 IDH2
2 positive regulation of DNA repair GO:0045739 9.4 EGFR MGMT
3 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.37 CDKN2A CDKN2C
4 response to organic cyclic compound GO:0014070 9.33 EGFR IDH1 MGMT
5 negative regulation of phosphorylation GO:0042326 9.32 CDKN2A CDKN2C
6 2-oxoglutarate metabolic process GO:0006103 9.26 IDH1 IDH2
7 isocitrate metabolic process GO:0006102 8.96 IDH1 IDH2
8 glyoxylate cycle GO:0006097 8.62 IDH1 IDH2

Molecular functions related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.54 CDKN2A CDKN2C EGFR
2 NAD binding GO:0051287 9.32 IDH1 IDH2
3 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 9.26 IDH1 IDH2
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.16 CDKN2A CDKN2C
5 isocitrate dehydrogenase activity GO:0004448 8.96 IDH1 IDH2
6 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.62 IDH1 IDH2

Sources for Anaplastic Oligodendroglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....